GLYT1 Inhibition Reduces Schizophrenia-like Symptoms Produced by Ketamine

被引：0
|
作者：
Driesen, Naomi R. [1 ,2 ]
Ranganathan, Mohini [1 ,3 ]
DeMartinis, Nicholas [4 ]
Bloch, Michael [1 ]
Morgan, Peter T. [1 ]
Gueorguieva, Raitza [1 ,5 ]
Ahn, Kyungheup [1 ,3 ]
D'Souza, Deepak C. [1 ,3 ]
Krystal, John H. [1 ,3 ]
机构：
[1] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA
[2] VA Connecticut Hlth Care Syst, Psychol, West Haven, CT USA
[3] VA Connecticut Hlth Care Syst, Psychiat, West Haven, CT USA
[4] Pfizer, Neurosci, Cambridge, MA USA
[5] Yale Univ, Sch Epidemiol & Publ Hlth, New Haven, CT USA
来源：
BIOLOGICAL PSYCHIATRY | 2015年 / 77卷 / 09期
关键词：
NMDA Receptor; Ketamine; Positive Symptoms; GlyT1; Inhibitor; Schizophrenia;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
561
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Influence of the dose of ketamine used on schizophrenia-like symptoms in mice: A correlation study with TH, GAD67, and PPAR-γ
    Rodrigues, Talita
    Bressan, Getulio Nicola
    Krum, Barbara Nunes
    Alexandre, Felix
    Soares, Antunes
    Fachinetto, Roselei
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2023, 233
  • [42] Ketamine enhances dopamine D1 receptor expression by modulating microRNAs in a ketamine-induced schizophrenia-like mouse model
    Li, Xiao-jin
    Yu, Juan-han
    Wu, Xue
    Zhu, Xiu-mei
    Lv, Peng
    Du, Zhe
    Lu, Yan
    Wu, Xu
    Yao, Jun
    NEUROTOXICOLOGY AND TERATOLOGY, 2022, 91
  • [43] Subclinical expression of schizophrenia-like symptoms in non-psychotic siblings of individuals with schizophrenia
    Smith, Matthew J.
    Barch, Deanna M.
    Thompson, Paul A.
    Csernansky, John G.
    SCHIZOPHRENIA RESEARCH, 2008, 103 (1-3) : 324 - 325
  • [44] Inhibition of activin signaling in the brain causes a schizophrenia-like behavior
    Ageta, H.
    Takashima, N.
    Inokuchi, K.
    NEUROSCIENCE RESEARCH, 2007, 58 : S122 - S122
  • [45] Pharmacological Characterization of the Novel GlyT1 Inhibitor BI 425809 on Target Engagement in-vivo and in Animal Models Related to Cognitive Symptoms of Schizophrenia
    Rosenbrock, Holger
    Giovannini, Riccardo
    Schmid, Bernhard
    Kramer, Gert
    Arban, Roberto
    Dorner-Ciossek, Cornelia
    BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 343S - 343S
  • [46] Reduction of Rapid Proliferating Tumour Cell Lines by Inhibition of the Specific Glycine Transporter GLYT1
    Bierhals, Christine Garcia
    Howard, Alison
    Hirst, Barry H.
    BIOMEDICINES, 2021, 9 (12)
  • [47] Combined Low Dose of Ketamine and Social Isolation: A Possible Model of Induced Chronic Schizophrenia-Like Symptoms in Male Albino Rats
    Estaphan, Suzanne
    Curpan, Alexandrina-Stefania
    Khalifa, Dalia
    Rashed, Laila
    Ciobica, Andrei
    Cantemir, Adrian
    Ciobica, Alin
    Trus, Constantin
    Ali, Mahmoud
    ShamsEldeen, Asmaa
    BRAIN SCIENCES, 2021, 11 (07)
  • [48] Reversal of schizophrenia-like symptoms and immune alterations in mice by immunomodulatory drugs
    Araujo, Tatiane da Silva
    Maia Chaves Filho, Adriano Jose
    Monte, Aline Santos
    de Gois Queiroz, Ana Isabelle
    Cordeiro, Rafaela Carneiro
    Souza Machado, Michel de Jesus
    Lima, Ricardo de Freitas
    de Lucena, David Freitas
    Maes, Michael
    Macedo, Danielle
    JOURNAL OF PSYCHIATRIC RESEARCH, 2017, 84 : 49 - 58
  • [49] Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis
    Morgan, Celia J. A.
    Curran, H. Valerie
    BRITISH JOURNAL OF PSYCHIATRY, 2008, 192 (04) : 306 - 307
  • [50] Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia
    Rosenbrock, Holger
    Desch, Michael
    Wunderlich, Glen
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2023, 273 (07) : 1557 - 1566
12345